Focused On-demand Library for Tumor necrosis factor receptor superfamily member 11A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Osteoclast differentiation factor receptor; Receptor activator of NF-KB

Alternative UPACC:

Q9Y6Q6; I4EC36; I4EC38; I4EC39; I7JE63; N0GVH0; Q59EP9


Tumor necrosis factor receptor superfamily member 11A, also known as the receptor activator of NF-KB and osteoclast differentiation factor receptor, plays a pivotal role in bone remodeling and immune system regulation. It serves as a receptor for TNFSF11/RANKL/TRANCE/OPGL, crucial for RANKL-mediated osteoclastogenesis, facilitating osteoclast development and function. This protein's interaction with EEIG1 enhances osteoclastogenesis by promoting NFATC1 transcription and activating PLCG2.

Therapeutic significance:

The protein's involvement in diseases such as Familial expansile osteolysis, early-onset Paget disease of bone 2, and autosomal recessive osteopetrosis 7 highlights its therapeutic potential. Targeting this protein could lead to innovative treatments for these bone disorders, offering hope for patients suffering from these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.